Leap Investments’s Vanda Pharmaceuticals VNDA Stock Holding History

Leap Investments’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-33,712	Closed	-$349K	–	576
2020 Q1	$349K	Buy	+33,712	New	+$418K	0.51%	32

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Leap Investments's VNDA Position: Q2 2020 in Review

Leap Investments sold out of Vanda Pharmaceuticals (VNDA) in Q2 2020, closing a stake of 33,712 shares — an estimated $349K sold.

Leap Investments first reported a position in VNDA in Q1 2020 and held it in 1 quarter. The position peaked at $349K in Q1 2020. 164 funds tracked by Wall St. Rank hold VNDA as of Q2 2020.

Leap Investments reported no remaining Vanda Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Leap Investments sold 33,712 Vanda Pharmaceuticals shares in Q2 2020, an estimated $349K.
Leap Investments first reported a position in Vanda Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Leap Investments's Vanda Pharmaceuticals position peaked at $349K in Q1 2020.
164 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.